National Institute of Allergy and Infectious Diseases (NIAID) clinical trial pipeline

16 trials changed in the last 30 days: 0 stopped, 8 with notable changes, 8 with minor changes only.

1. Notable

   Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus…Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza

   Primary completion pushed from Sep 29, 2026 to Sep 29, 2027

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1· NCT07215871· Registry history of NCT07215871 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

2. Notable

   Mechanistic Biology of Primary Immunodeficiency Disorders

   Primary completion pushed from Dec 31, 2029 to Dec 31, 2030

   And 1 more change in the last 30 days

   National Institute of Allergy and Infectious Diseases (NIAID)·Not specified· NCT03394053· Registry history of NCT03394053 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

3. Notable

   Combination HIV-Specific Broadly Neutralizing Monoclonal…Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

   Primary endpoint(s) modified

   Also in this update: Primary completion pushed from Apr 6, 2028 to Jul 17, 2028; Trial sites reduced: 36 → 12 locations

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2· NCT05719441· Registry history of NCT05719441 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

4. Notable

   ALL IN LUNG · Tocilizumab in Lung Transplantation

   Enrollment reduced: 350 → 100 participants

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2· NCT06033196· Registry history of NCT06033196 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

5. Notable

   Orally Ingested Yeast Modified to Express a Tetra-specific…Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile

   Enrollment reduced: 86 → 56 participants

   Also in this update: Trial arms changed: 14 → 8

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1· NCT07649096· Registry history of NCT07649096 on ClinicalTrials.gov (opens the registry)

   Oct 6, 2026

6. Notable

   Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis…Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

   Recruitment opened

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2· NCT07124559· Registry history of NCT07124559 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

7. Notable

   CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy…CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

   Recruitment opened

   Also in this update: Start date pushed from Oct 1, 2026 to Oct 19, 2026

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1· NCT07757802· Registry history of NCT07757802 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

8. Notable

   Tocilizumab in Cardiac Transplantation

   Results posted: Sep 29, 2026

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2· NCT03644667· Registry history of NCT03644667 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.